关于2型糖尿病合并慢性肾脏病患者应用胰岛素治疗的专家指导建议

2017-10-30 中国内分泌相关专家小组(统称) 中国糖尿病杂志.2017.25(10):865-868.

T2DM 患者较正常人群易合并慢性肾脏病(CKD)。上海市区≥30岁T2DM 患者CKD患病率可达63.9%。2015年美国肾脏数据系统显示,在引起终末期肾脏病(ESRD)的主因中,糖尿病约占44%。合并CKD的T2DM 患者,由于血糖稳态和降糖药物代谢发生改变,低血糖风险更高,血糖管理更加复杂。本文综合了内分泌专家和肾内科专家的建议,对T2DM 合并CKD患者在使用胰岛素上的临床经验进行汇总,并

中文标题:

关于2型糖尿病合并慢性肾脏病患者应用胰岛素治疗的专家指导建议

发布日期:

2017-10-30

简要介绍:

T2DM 患者较正常人群易合并慢性肾脏病(CKD)。上海市区≥30岁T2DM 患者CKD患病率可达63.9%。2015年美国肾脏数据系统显示,在引起终末期肾脏病(ESRD)的主因中,糖尿病约占44%。合并CKD的T2DM 患者,由于血糖稳态和降糖药物代谢发生改变,低血糖风险更高,血糖管理更加复杂。本文综合了内分泌专家和肾内科专家的建议,对T2DM 合并CKD患者在使用胰岛素上的临床经验进行汇总,并提出临床指导建议。

 

拓展指南:糖尿病相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=关于2型糖尿病合并慢性肾脏病患者应用胰岛素治疗的专家指导建议)] GetToolGuiderByIdResponse(projectId=1, id=975a71c001522852, title=关于2型糖尿病合并慢性肾脏病患者应用胰岛素治疗的专家指导建议, enTitle=, guiderFrom=中国糖尿病杂志.2017.25(10):865-868., authorId=null, author=, summary=T2DM 患者较正常人群易合并慢性肾脏病(CKD)。上海市区≥30岁T2DM 患者CKD患病率可达63.9%。2015年美国肾脏数据系统显示,在引起终末期肾脏病(ESRD)的主因中,糖尿病约占44%。合并CKD的T2DM 患者,由于血糖稳态和降糖药物代谢发生改变,低血糖风险更高,血糖管理更加复杂。本文综合了内分泌专家和肾内科专家的建议,对T2DM 合并CKD患者在使用胰岛素上的临床经验进行汇总,并, cover=, journalId=null, articlesId=null, associationId=666, associationName=中国内分泌相关专家小组(统称), associationIntro=这是一个统称,其下指南和专家共识均由国内内分泌领域的专家制定。, copyright=0, guiderPublishedTime=Mon Oct 30 00:00:00 CST 2017, originalUrl=, linkOutUrl=, content=<P>T2DM 患者较正常人群易合并慢性肾脏病(CKD)。上海市区≥30岁T2DM 患者CKD患病率可达63.9%。2015年美国肾脏数据系统显示,在引起终末期肾脏病(ESRD)的主因中,糖尿病约占44%。合并CKD的T2DM 患者,由于血糖稳态和降糖药物代谢发生改变,低血糖风险更高,血糖管理更加复杂。本文综合了内分泌专家和肾内科专家的建议,对T2DM 合并CKD患者在使用胰岛素上的临床经验进行汇总,并提出临床指导建议。 </P> <P> </P>拓展指南:<strong>与<font color=red>糖尿病</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=ed10a1c0015200a4" title="2017 TES科学声明:糖尿病性微血管病" target=_blank>2017 TES科学声明:糖尿病性微血管病</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=5d0d21c00151830e" title="2017年ACP《2型糖尿病口服药物治疗临床实践指南》解读" target=_blank>2017年ACP《2型糖尿病口服药物治疗临床实践指南》解读</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=3aad31c00151809e" title="ADA 关于糖尿病合并高血压的最新立场声明的解读" target=_blank>ADA 关于糖尿病合并高血压的最新立场声明的解读</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=44b6f1c00151a1a2" title="2017 VA/DoD临床实践指南:2型糖尿病的管理" target=_blank>2017 VA/DoD临床实践指南:2型糖尿病的管理</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=45b691c00151334f" title="2017 KDA立场声明:降糖药物治疗成人2型糖尿病" target=_blank>2017 KDA立场声明:降糖药物治疗成人2型糖尿病</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E7%B3%96%E5%B0%BF%E7%97%85" target=_blank>有关糖尿病更多指南</a></ul>, tagList=[TagDto(tagId=2052, tagName=2型糖尿病), TagDto(tagId=11742, tagName=慢性肾脏), TagDto(tagId=31163, tagName=胰岛素治疗)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=8, categoryName=糖尿病, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其他, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6277, appHits=488, showAppHits=6, pcHits=4376, showPcHits=1859, likes=156, shares=17, comments=11, approvalStatus=1, publishedTime=Wed Nov 22 21:59:32 CST 2017, publishedTimeString=2017-10-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Wed Nov 22 21:59:32 CST 2017, updatedBy=null, updatedName=null, updatedTime=Wed Jan 03 03:06:39 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=关于2型糖尿病合并慢性肾脏病患者应用胰岛素治疗的专家指导建议)])
关于2型糖尿病合并慢性肾脏病患者应用胰岛素治疗的专家指导建议
下载请点击:
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=972612, encodeId=43659e261291, content=2型糖尿病胰岛素治疗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7975280135, createdName=1483f8cem53(暂无昵称), createdTime=Thu Jun 10 18:00:05 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807982, encodeId=273080e98239, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:27:22 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807981, encodeId=8ab680e981bf, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:27:19 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807980, encodeId=d38f80e98061, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:27:17 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807979, encodeId=ff9380e979de, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:27:13 CST 2020, time=2020-08-12, status=1, ipAttribution=)]
    2021-06-10 1483f8cem53(暂无昵称)

    2型糖尿病胰岛素治疗

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=972612, encodeId=43659e261291, content=2型糖尿病胰岛素治疗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7975280135, createdName=1483f8cem53(暂无昵称), createdTime=Thu Jun 10 18:00:05 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807982, encodeId=273080e98239, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:27:22 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807981, encodeId=8ab680e981bf, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:27:19 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807980, encodeId=d38f80e98061, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:27:17 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807979, encodeId=ff9380e979de, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:27:13 CST 2020, time=2020-08-12, status=1, ipAttribution=)]
    2020-08-12 14643f34m67暂无昵称

    学习好资料

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=972612, encodeId=43659e261291, content=2型糖尿病胰岛素治疗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7975280135, createdName=1483f8cem53(暂无昵称), createdTime=Thu Jun 10 18:00:05 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807982, encodeId=273080e98239, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:27:22 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807981, encodeId=8ab680e981bf, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:27:19 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807980, encodeId=d38f80e98061, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:27:17 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807979, encodeId=ff9380e979de, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:27:13 CST 2020, time=2020-08-12, status=1, ipAttribution=)]
    2020-08-12 14643f34m67暂无昵称

    学习好资料

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=972612, encodeId=43659e261291, content=2型糖尿病胰岛素治疗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7975280135, createdName=1483f8cem53(暂无昵称), createdTime=Thu Jun 10 18:00:05 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807982, encodeId=273080e98239, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:27:22 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807981, encodeId=8ab680e981bf, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:27:19 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807980, encodeId=d38f80e98061, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:27:17 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807979, encodeId=ff9380e979de, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:27:13 CST 2020, time=2020-08-12, status=1, ipAttribution=)]
    2020-08-12 14643f34m67暂无昵称

    学习好资料

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=972612, encodeId=43659e261291, content=2型糖尿病胰岛素治疗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7975280135, createdName=1483f8cem53(暂无昵称), createdTime=Thu Jun 10 18:00:05 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807982, encodeId=273080e98239, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:27:22 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807981, encodeId=8ab680e981bf, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:27:19 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807980, encodeId=d38f80e98061, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:27:17 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807979, encodeId=ff9380e979de, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 11:27:13 CST 2020, time=2020-08-12, status=1, ipAttribution=)]
    2020-08-12 14643f34m67暂无昵称

    学习好资料

    0